PipelineReview.com17 小时
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic ...
CHENGDU, China I 8, 2025 I Keymed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has ...
Keymed Biosciences Inc.: Keymed Biosciences Announces Approval of Stapokibart For the ...
Keymed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental ...